Blood Lipopolysaccharide (LPS) Rifaximin Study

NCT02124512 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Obese
Insulin Resistance
Metabolic Syndrome

Interventions

DRUG: Rifaximin SSD
OTHER: Placebo

Sponsor

Philip Kern

Collaborators

[object Object]